RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics.

Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Dr. Arnold Lippa, Chief Scientific Officer, Executive Chairman of the Board and Interim President and Interim Chief Executive Officer was an invited speaker on April 23^rd at the 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics, where he presented data and discussed the potential use of AMPAkines for the treatment of certain GRI (ionotropic glutamate receptors) disorders. GRI disorders refers to a family of very rare, de novo, missense mutations in the genes responsible for the construction of ionotropic glutamate receptor proteins that, when assembled and activated by glutamate, allow the transport of cations through the neuronal membrane and into the cell. Patients with GRI disorders display a broad spectrum of symptoms, including cognitive deficits, delayed development, autism spectrum disorder behavioral patterns, hypotonia, respiratory difficulties and treatment resistant seizures. It is believed that various GRI related symptoms may be due to alterations in the GRI genes, including GRIA, GRIN and GRIK, genes coding for proteins associated with the AMPA, NMDA and kainite glutamate receptors, respectively.